RGEN

Repligen Corporation

$173.98

-2.77%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryUnited States

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits.

Source: Yahoo Finance
AI summary

Price & performance

1M-4.8%
3M+22.7%
YTD+5.2%
1Y+16.0%
52-week range—
Beta1.45
Full chart and returns against a benchmark

Q-Score

49/ 100

Quality against peers; 50 is the peer median.

Growth46
Risk59
Performance56
Valuation31
Profitability56
Leverage60
Sentiment58
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$738.3M+16.4%
Net income$48.9M
Net margin6.6%+10.6 pts
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsFeb 26, 2026
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

RGENIndustryP/E—49.36P/S13.813.73EV/EBITDA113.8823.12P/B5.323.92PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Oct 27next report, before the open
EPS estimate$0.46
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate